COVID-19: monoclonal antibodies or antivirals for non-hospitalised patients – clinical update

This summary covers the key points from the latest guidance on the use of nMABs or antivirals for non-hospitalised patients with COVID-19; read on to learn about the supporting evidence, eligibility criteria, and key side effects of these treatments.
COVID-19: monoclonal antibodies or antivirals for non-hospitalised patients – clinical update

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date
Register

Existing members Sign in

Sorry, we need to confirm your details before you can access this content.

If you have just signed up to OnMedica, you are seeing this message because we couldn’t automatically verify that you are a practising doctor in the UK. Please check your email inbox as we may need a few more details to validate your OnMedica membership. If you haven’t received an email from us or you need assistance, please contact customer.services@onmedica.com.